INT162057

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 9.78
Pain Relevance 1.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (TNFSF11) extracellular space (TNFSF11) extracellular region (TNFSF11)
plasma membrane (TNFSF11) intracellular (TNFSF11) response to stress (TNFSF11)
Anatomy Link Frequency
osteoclast 2
osteoblasts 1
TNFSF11 (Homo sapiens)
Pain Link Frequency Relevance Heat
Osteoarthritis 265 99.30 Very High Very High Very High
imagery 19 98.76 Very High Very High Very High
Pain 24 92.48 High High
Spinal cord 1 91.48 High High
Arthritis 25 79.60 Quite High
Adalimumab 1 76.00 Quite High
methotrexate 10 74.56 Quite High
Bioavailability 4 74.00 Quite High
cytokine 40 73.52 Quite High
Infliximab 6 73.24 Quite High
Disease Link Frequency Relevance Heat
Cancer 317 100.00 Very High Very High Very High
Hypercalcemia 80 99.92 Very High Very High Very High
Osteoarthritis 265 99.30 Very High Very High Very High
Osteoporosis 350 98.84 Very High Very High Very High
Apoptosis 30 98.76 Very High Very High Very High
Immunotherapy Of Cancer 8 98.44 Very High Very High Very High
Metastasis 391 98.16 Very High Very High Very High
Osteolysis 64 97.60 Very High Very High Very High
Pain 24 92.48 High High
Spinal Cord Compression 1 91.96 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The RANKL expression level (Figure 2b) was significantly decreased with CS and with the combination of the two drugs.
Negative_regulation (decreased) of RANKL
1) Confidence 0.58 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246236 Disease Relevance 0 Pain Relevance 0
On the OPG and RANKL system, our data revealed that CS can modulate the expression of these molecules by increasing OPG and decreasing the gene expression level of RANKL, thereby increasing the mRNA ratio of OPG/RANKL.
Negative_regulation (decreasing) of RANKL
2) Confidence 0.58 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246236 Disease Relevance 0.06 Pain Relevance 0.07
Under this condition, CS alone and in combination with GS tended to downregulate the RANKL level.
Negative_regulation (downregulate) of RANKL
3) Confidence 0.50 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246236 Disease Relevance 0.06 Pain Relevance 0.06
Denosumab, a fully human monoclonal antibody, decreases bone resorption by inhibiting RANKL, which mediates osteoclast activity.
Negative_regulation (inhibiting) of RANKL in osteoclast associated with hypercalcemia
4) Confidence 0.44 Published 2010 Journal J. Bone Miner. Res. Section Abstract Doc Link 19653815 Disease Relevance 0.90 Pain Relevance 0.14
We previously demonstrated that OA subchondral bone osteoblasts can be discriminated into two subgroups and that both OPG and RANKL expression levels, and consequently the expression ratio of OPG/RANKL, differ according to the metabolic state of human OA subchondral bone osteoblasts: OPG/RANKL is decreased in L- and increased in H-OA osteoblasts[11].
Negative_regulation (decreased) of RANKL in osteoblasts associated with osteoarthritis
5) Confidence 0.43 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246236 Disease Relevance 0.95 Pain Relevance 0.40
The human monoclonal antibody denosumab, previously known as AMG 162, specifically binds and inhibits RANKL activity.
Negative_regulation (inhibits) of RANKL
6) Confidence 0.30 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2686344 Disease Relevance 0.39 Pain Relevance 0
Recombinant OPG construct was one of the first RANKL inhibitors to be used in clinical trials for osteolytic metastatic disease [69].
Negative_regulation (inhibitors) of RANKL associated with metastasis
7) Confidence 0.25 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 1.52 Pain Relevance 0.07
OPG is a negative regulator of the RANK/RANKL pathway and prevents RANK-RANKL interaction by sequestering RANKL.
Negative_regulation (regulator) of RANKL
8) Confidence 0.25 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 0.69 Pain Relevance 0.04
However, blocking the OPG/RANK/RANKL pathway with RANK-Fc had no effect on tumor cells in nonosseous sites; the decrease in tumor burden following inhibition of the tumor-mediated osteolysis is an indirect effect secondary to interruption of the vicious cycle of osteolytic metastasis [43-45].
Negative_regulation (decrease) of RANKL associated with cancer, osteolysis and metastasis
9) Confidence 0.25 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 1.58 Pain Relevance 0.03
However, blocking the OPG/RANK/RANKL pathway with RANK-Fc had no effect on tumor cells in nonosseous sites; the decrease in tumor burden following inhibition of the tumor-mediated osteolysis is an indirect effect secondary to interruption of the vicious cycle of osteolytic metastasis [43-45].
Negative_regulation (blocking) of RANKL associated with cancer, osteolysis and metastasis
10) Confidence 0.25 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 1.51 Pain Relevance 0.03
Bisphosphonate therapy can decrease RANKL levels and promote osteoclast apoptosis.
Negative_regulation (decrease) of RANKL in osteoclast associated with apoptosis
11) Confidence 0.16 Published 2009 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2770547 Disease Relevance 0.33 Pain Relevance 0.34
A decrease in the level of RANKL in PC3/OPN (RGA) as compared with PC3/OPN cells suggests that ?
Negative_regulation (decrease) of RANKL
12) Confidence 0.14 Published 2007 Journal Mol Cancer Section Body Doc Link PMC1828067 Disease Relevance 1.02 Pain Relevance 0.08
Clinical research is also evaluating rankl inhibitors, and other antiresorptive options and anabolic therapies are expected to possibly play a future role in the prevention of fracture in the patient with cancer.
Negative_regulation (inhibitors) of rankl associated with cancer
13) Confidence 0.13 Published 2008 Journal Current Oncology Section Body Doc Link PMC2216420 Disease Relevance 0.63 Pain Relevance 0
That is, Kafka both records and shapes his hypnagogic imagery and it's meaning while writing in what I have described as a trance-state during sleep-, but also sensory- and social-deprivation.
Negative_regulation (deprivation) of trance-state associated with imagery
14) Confidence 0.02 Published 2010 Journal Philos Ethics Humanit Med Section Body Doc Link PMC2944142 Disease Relevance 0.15 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox